Cambrooke Therapeutics logo
Cambrooke Therapeutics Funds raised:£64,000,000

Ruffena Capital helps Cambrooke Therapeutics to be acquired by Ajinomoto North America for USD$64m.

Nov 2017

Ruffena Capital introduced Ajinomoto North America who subsequently acquired Cambrooke Therapeutics in November, 2017 for approximately $64 million. The transaction makes Cambrooke a wholly owned subsidiary of Ajinomoto.


For many decades Ajinomoto has contributed to global health and wellness through specialty applications of amino acid technologies. Today, the company is becoming increasingly involved in creating solutions for specialty nutrition. Ajinomoto’s acquisition of Cambrooke supports Cambrooke’s focus on specialty nutrition and enables a pathway for Cambrooke’s use of Ajinomoto’s core technologies on metabolic and ketogenic therapy products, as well as accelerated development of better nutritional solutions for more chronic conditions.

Ajinomoto North America, Inc. is a wholly owned subsidiary of Ajinomoto Co., Inc. and is a recognized global leader in the research, development, manufacture and sale of amino acid-based products for the pharmaceutical, nutraceutical, sports nutrition, health and beauty industries as well as food ingredients and consumer food products.

Established in 2013, Ruffena Capital has evolved to become a boutique private equity advisory business with its own investment platform - focused on raising true growth capital or alternative finance, typically in the £2-10m range for its clients. Ruffena’s investors are largely a private audience of experienced UK and international investors, funds, family offices and certain wealth managers, who prefer established, highly tangible opportunities that can demonstrate the ability to scale and generate returns. Ruffena secured or advised upon over £42m going into client projects over the 2016-17 financial year. In the current year this has risen significantly and Ruffena has also had two clients IPO and one full exit in 2017-18. Ruffena does take on some earlier stage projects, however they must emphatically demonstrate thorough planning; tangible commercial potential; and a workable investment proposition.